The estimated Net Worth of Bryan Ball is at least $190 mil dollars as of 3 October 2019. Mr Ball owns over 5,000 units of Intercept Pharmaceuticals Inc stock worth over $190,000 and over the last 6 years he sold ICPT stock worth over $0.
Mr has made over 2 trades of the Intercept Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ICPT stock worth $70,900 on 3 October 2019.
The largest trade he's ever made was buying 5,000 units of Intercept Pharmaceuticals Inc stock on 3 October 2019 worth over $70,900. On average, Mr trades about 909 units every 10 days since 2019. As of 3 October 2019 he still owns at least 10,000 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Mr Ball stock trades at the bottom of the page.
Bryan Ball is the Chief Quality Officer & Sr. VP of Operations at Intercept Pharmaceuticals Inc.
Mr Ball is 51, he's been the Chief Quality Officer & Sr. VP of Operations of Intercept Pharmaceuticals Inc since . There are 16 older and 5 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Bryan's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 305 MADISON AVENUE, MORRISTOWN, NJ, 07960.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, eFrancesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: